Handelsavisen
prelaunch
Companies Healthcare AONC.PK
AO
AONC.PK OTC Healthcare Facilities & Services

American Oncology Network Inc

$10,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-0,2 %
ROE
-2,5 %
Net margin
-0,5 %
Debt / equity
1,36
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

American Oncology Network Inc provides oncology services and operates cancer treatment centers, generating revenue primarily through patient care and insurance reimbursements.

Business. American Oncology Network Inc (AONC.PK) is a healthcare services company that operates within the healthcare facilities and services industry. The firm is headquartered in the United States and is listed on the OTC market. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-2,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning AONC.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to AONC.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    American Oncology Network Inc (AONC.PK) is a healthcare services company that operates within the healthcare facilities and services industry. The firm is headquartered in the United States and is listed on the OTC market. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    American Oncology Network Inc has a debt-to-equity ratio of 1.36, indicating a moderate level of leverage, while its current ratio of 1.69 suggests it has sufficient short-term assets to cover its liabilities. The company's liquidity position is assessed as medium, with negative free cash flow of -$1.96 million and operating cash flow of -$329,000, signaling potential challenges in maintaining operational liquidity.

    Profitability metrics show a return on equity of -2.45% and a return on assets of -0.44%, both significantly below the industry median for healthcare facilities and services. The company reported a net loss of $1.49 million and an operating loss of $491,000, indicating a lack of profitability compared to industry peers.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts that could impact its operations.

    The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The absence of positive revenue growth, combined with negative operating and net income, suggests a challenging operating environment.

    Risk factors include a medium liquidity risk due to negative free cash flow and a debt load that exceeds equity. The company has a low dilution risk, with no near-term pressure for additional equity issuance. However, the negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations.

    Recent filings and transcripts have not disclosed any material events that would significantly alter the company's financial or operational outlook. The company remains in a loss-making position, with no clear path to profitability in the near term.

    Key takeaways
    • American Oncology Network Inc is operating at a loss, with negative net income and operating income.
    • The company's liquidity is constrained, with negative free cash flow and a debt-to-equity ratio of 1.36.
    • Profitability metrics are well below industry medians, indicating poor performance relative to peers.
    • The company lacks geographic and segment diversification, increasing its exposure to regional and operational risks.
    • No significant growth in revenue has been reported, and the outlook for profitability remains uncertain.
    • "margin_outlook_rationale": "Margins are expected to remain under pressure due to the company's current operating losses and lack of gross profit growth.",

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue grew 37.5% year-over-year to $1.76 billion, demonstrating strong top-line expansion momentum.

    Operating income improved 64.5% year-over-year, indicating significant progress in operational efficiency and cost management.

    Free cash flow improved 38.7% year-over-year, showing better cash generation despite ongoing negative absolute values.

    Long-term debt decreased from $86.4 million to $95.5 million over the period, though recent trends show reduction.

    Gross profit reached $117.8 million, providing a substantial base for potential operating leverage improvements.

    BEAR CASE · 4

    The company carries a high credit risk flag, signaling significant concerns regarding its ability to meet obligations.

    Net margin of -0.49% remains well below the 4.15% cohort median, highlighting persistent profitability challenges.

    Debt-to-equity ratio of 1.36 is in the bottom quartile, indicating excessive leverage compared to peers.

    Free cash flow remains negative at -$43.1 million, creating reliance on external financing for operations.

    In focus — financials by report

    Valuation FY

    Market price
    $10,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $60.6M
    Net cash
    -$58.6M
    Current ratio
    1.7
    Debt / equity
    1.4
    ROA
    -0.4%
    ROE
    -2.5%
    Cash conversion
    22.0%
    CapEx / revenue
    -0.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-0,2 %Below median
    Net Margin-0,5 %Below median
    ROE-2,5 %Bottom quartile
    Capex / Rev-0,9 %Above P75
    D/E1,36Bottom quartile
    Cash Conv0,22Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • American Oncology Network Inc Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    8.4Kshares short0.0% vs prior
    323days to cover
    13fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    AONC.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage